These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

678 related articles for article (PubMed ID: 33261536)

  • 1. Bacteriophages for ESKAPE: role in pathogenicity and measures of control.
    Patil A; Banerji R; Kanojiya P; Koratkar S; Saroj S
    Expert Rev Anti Infect Ther; 2021 Jul; 19(7):845-865. PubMed ID: 33261536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bacteriophage therapy against ESKAPE bacterial pathogens: Current status, strategies, challenges, and future scope.
    Kulshrestha M; Tiwari M; Tiwari V
    Microb Pathog; 2024 Jan; 186():106467. PubMed ID: 38036110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fighting Pathogenic Bacteria on Two Fronts: Phages and Antibiotics as Combined Strategy.
    Tagliaferri TL; Jansen M; Horz HP
    Front Cell Infect Microbiol; 2019; 9():22. PubMed ID: 30834237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel antimicrobial agents for combating antibiotic-resistant bacteria.
    Chang RYK; Nang SC; Chan HK; Li J
    Adv Drug Deliv Rev; 2022 Aug; 187():114378. PubMed ID: 35671882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Systematic and Critical Review of Bacteriophage Therapy Against Multidrug-resistant ESKAPE Organisms in Humans.
    El Haddad L; Harb CP; Gebara MA; Stibich MA; Chemaly RF
    Clin Infect Dis; 2019 Jun; 69(1):167-178. PubMed ID: 30395179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging Strategies to Combat ESKAPE Pathogens in the Era of Antimicrobial Resistance: A Review.
    Mulani MS; Kamble EE; Kumkar SN; Tawre MS; Pardesi KR
    Front Microbiol; 2019; 10():539. PubMed ID: 30988669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PlyKp104, a Novel Phage Lysin for the Treatment of Klebsiella pneumoniae, Pseudomonas aeruginosa, and Other Gram-Negative ESKAPE Pathogens.
    Euler CW; Raz A; Hernandez A; Serrano A; Xu S; Andersson M; Zou G; Zhang Y; Fischetti VA; Li J
    Antimicrob Agents Chemother; 2023 May; 67(5):e0151922. PubMed ID: 37098944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies to Overcome Antimicrobial Resistance in Nosocomial Infections, A Review and Update.
    Bakhtiyari N; Farajnia S; Ghasemali S; Farajnia S; Pormohammad A; Saeidvafa S
    Infect Disord Drug Targets; 2024; 24(6):e260124226226. PubMed ID: 38284691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preliminary survey of local bacteriophages with lytic activity against multi-drug resistant bacteria.
    Latz S; Wahida A; Arif A; Häfner H; Hoß M; Ritter K; Horz HP
    J Basic Microbiol; 2016 Oct; 56(10):1117-1123. PubMed ID: 27194637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of Novel
    Mulani MS; Kumkar SN; Pardesi KR
    Microbiol Spectr; 2022 Dec; 10(6):e0199422. PubMed ID: 36374021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR in Modulating Antibiotic Resistance of ESKAPE Pathogens.
    Saha U; Gondi R; Patil A; Saroj SD
    Mol Biotechnol; 2023 Jan; 65(1):1-16. PubMed ID: 35939207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phage Therapy in the Resistance Era: Where Do We Stand and Where Are We Going?
    Luong T; Salabarria AC; Roach DR
    Clin Ther; 2020 Sep; 42(9):1659-1680. PubMed ID: 32883528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phage therapy: an alternative treatment modality for MDR bacterial infections.
    Pal N; Sharma P; Kumawat M; Singh S; Verma V; Tiwari RR; Sarma DK; Nagpal R; Kumar M
    Infect Dis (Lond); 2024 Oct; 56(10):785-817. PubMed ID: 39017931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bacteriophages: A Therapy Concept against Multi-Drug-Resistant Bacteria.
    Rohde C; Wittmann J; Kutter E
    Surg Infect (Larchmt); 2018; 19(8):737-744. PubMed ID: 30256176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Navigating ESKAPE Pathogens: Considerations and Caveats for Animal Infection Models Development.
    Yu H; Xu Y; Imani S; Zhao Z; Ullah S; Wang Q
    ACS Infect Dis; 2024 Jul; 10(7):2336-2355. PubMed ID: 38866389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Light Modulates Important Pathogenic Determinants and Virulence in ESKAPE Pathogens Acinetobacter baumannii, Pseudomonas aeruginosa, and Staphylococcus aureus.
    Tuttobene MR; Pérez JF; Pavesi ES; Perez Mora B; Biancotti D; Cribb P; Altilio M; Müller GL; Gramajo H; Tamagno G; Ramírez MS; Diacovich L; Mussi MA
    J Bacteriol; 2021 Feb; 203(5):. PubMed ID: 33288627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of four virulent Klebsiella pneumoniae bacteriophages, and evaluation of their potential use in complex phage preparation.
    Zurabov F; Zhilenkov E
    Virol J; 2021 Jan; 18(1):9. PubMed ID: 33407669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial Resistance in ESKAPE Pathogens.
    De Oliveira DMP; Forde BM; Kidd TJ; Harris PNA; Schembri MA; Beatson SA; Paterson DL; Walker MJ
    Clin Microbiol Rev; 2020 Jun; 33(3):. PubMed ID: 32404435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Photoinactivation of ESKAPE pathogens: overview of novel therapeutic strategy.
    Nakonieczna J; Wozniak A; Pieranski M; Rapacka-Zdonczyk A; Ogonowska P; Grinholc M
    Future Med Chem; 2019 Mar; 11(5):443-461. PubMed ID: 30901231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bacteriophage treatment as an alternative therapy for multidrug-resistant bacteria.
    Alqahtani A
    Saudi Med J; 2023 Dec; 44(12):1222-1231. PubMed ID: 38016738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.